Contact Us

Experimental drug slows progression of Alzheimer’s: Study

An experimental Alzheimer's drug from Eisai and Biogen slowed cognitive decline in a closely watched trial but may carry a risk of serious side effects for certain patients, according to detailed data presented on Tuesday.

  • 6
  • 8
"These peer-reviewed, published results show lecanemab will provide patients more time to participate in daily life and live independently. It could mean many months more of recognizing their spouse, children and grandchildren," the U.S.-based Alzheimer's Association said Tuesday in a statement.